Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BLU-701 in EGFR-Mutant Non-Small Cell Lung Cancer
NCT05153408Phase 1Terminated
- Sponsor
- Blueprint Medicines
- Start
- Jan 2022
- Primary completion
- Dec 2022
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label trial of blu-701 in non-small cell lung cancer (NSCLC), sponsored by Blueprint Medicines. Primary endpoints: Maximum Tolerated Dose at 12 months, Recommended Phase 2 Dose at 12 months and 2 more. Started Jan 2022; status: terminated.
02
Drugs
blu-701
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05153408.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05153408.